文献速递脑血管病

新型溶栓药caADAMTS13与临床溶栓药在小鼠卒中模型的比较

Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model.
PubMed 文献 · Stroke · 2025-04-02

本研究在小鼠氯化铁诱导的远端大脑中动脉闭塞模型中,直接比较了caADAMTS13与r-tPA、TNK及载体对照的溶栓效果。结果显示caADAMTS13治疗组早期再灌注最佳,24小时脑血流更高,行为缺陷缺失,梗死体积更小且出血程度更低。结论提示caADAMTS13对富含血小板血栓的溶栓效果可能优于现有卒中治疗。

要点

  • caADAMTS13治疗组1小时再灌注改善最显著。
  • caADAMTS13和r-tPA组24小时卒中区脑血流高于TNK组。
  • caADAMTS13组行为缺陷缺失,24小时梗死体积更小,出血程度更低。

核心结论

  • 总体提示caADAMTS13对富含血小板血栓的溶栓效果优于现有卒中治疗,该领域存在未满足的临床需求。

研究设计与样本

  • 在小鼠氯化铁诱导的远端大脑中动脉闭塞模型中,直接比较caADAMTS13、r-tPA、TNK和载体对照。
  • 治疗在氯化铁应用后1小时静脉给药,采用推注或推注后输注方式。
  • 激光散斑对比成像测量治疗后1小时内早期再灌注,磁共振成像测量24小时脑血流和病灶体积。

主要发现

  • 治疗后1小时再灌注在caADAMTS13治疗动物中最大。
  • 治疗后24小时卒中影响的低灌注区内脑血流在caADAMTS13和r-tPA组较高,但TNK组未升高。
  • caADAMTS13治疗小鼠未出现初始行为缺陷,24小时病灶体积更小,出血程度降低。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: r-tPA (recombinant tissue-type plasminogen activator) and its variant, TNK (tenecteplase), are the currently approved thrombolytic drugs for the treatment of acute ischemic stroke, but they are ineffective in a proportion of patients due to r-tPA resistance of platelet-rich thrombi. A novel thrombolytic, caADAMTS13 (constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) has been shown to improve experimental stroke outcomes where platelet-rich thrombi are present but have not been directly compared with r-tPA or TNK. METHODS: We conducted a direct comparison of caADAMTS13 versus r-tPA versus TNK versus vehicle control in the ferric chloride-mediated distal middle cerebral artery occlusion model in mice, which features platelet and VWF (von Willebrand Factor)-rich thrombi that reproduce r-tPA-resistant occlusion. Treatments were administered intravenously 1 hour after ferric chloride application by bolus injection or bolus followed by infusion, as translationally applicable. Laser speckle contrast imaging measured early reperfusion over the hour following treatment, and magnetic resonance imaging measured cerebral blood flow and lesion volume at 24 hours. RESULTS: Reperfusion 1 hour after treatment was greatest in caADAMTS13-treated animals. Later cerebral blood flow, 24 hours post-treatment, within the stroke-affected hypoperfused area was higher in caADAMTS13 and r-tPA but not TNK-treated mice. Functionally, this led to the absence of an initial behavioral deficit in caADAMTS13-treated mice, alongside a smaller lesion volume at 24 hours and reduced extent of bleeding. CONCLUSIONS: These findings demonstrate an overall suggestion that caADAMTS13 has improved thrombolytic efficacy, compared with current stroke treatments, against platelet-rich thrombi, for which there is currently an unmet clinical need.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Roberts L, Coutts G, Dickie BR, et al. Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model. Stroke. 2025. PMID: 40171654. doi:10.1161/STROKEAHA.125.050848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。